Dear colleague,

We are proud to share with you our first newsletter dedicated to the global re-launch of our brands Flexbumin and HumanAlbumin.

 

A new story
must be written

Human albumin has been on the market for 70 years. Yet, the market is still growing, and we are witnessing a strong demand in Asia, particularly in China due to an increased incidence of cirrhosis.

For Takeda, it's the right time to re-launch HumanAlbumin and Flexbumin.

Especially now, with the competition (Grifols) potentially coming in with a new Albumin Bag soon!

The Albu-Team is working closely with our Takeda Teams in our strategic markets: China, USA and India.

China Kick-off meeting

 
 

Ipsos, Clarion Healthcare, IQVIA, Havas Health & You, Takeda China and Takeda Global teams

We are running intensive market research in these three countries. For example, there are over 1600 interviews planned across China.

Our objective is to rethink our communication and services to answer the needs of our customers.

Accelerated
Market Research

China - September 2019

Where?

Tier 1 city - Shanghai

Tier 2 city - Chengdu

Tier 3 city - Zhengzhou

What?

Qualitative research (one on one) with Ipsos

Mystery shopper visits to retail pharmacists

Data analysis from IQVIA

Whom?

Over 1600 Physicians and
Retail Pharmacists interviewed

On the road
with the Albu-Team

Christian at the front-line

curiously searching for insights

 
 

Ipsos, Clarion Healthcare, IQVIA, Havas Health & You, Takeda China and Takeda Global teams

 

Milestones

Questions
please contact:

 

Frederic Chapuis
Gobal Commercial Lead
Rare Specialty Care
(Albumin/Coagulation)
Immunology Franchise
frederic.chapuis@takeda.com

 

Christian Hoffmann
Insights lead - Immunology
(BioT, Transplan, New Products)
Patient Value & Product Strategy
(PVPS)
carlchristian.hoffmann@takeda.com

 

We would love to hear from you!

 

Stay tuned for more updates soon!

 

Yours,

The Albu-Team